Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: March 08, 2024
Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone.
Journal: Nature
Published: April 17, 2023
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: January 19, 2022
Showing 1-3 of 3
Last Updated: 09/26/2026